193 related articles for article (PubMed ID: 23039927)
1. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.
Tell V; Holzer M; Herrmann L; Mahmoud KA; Schächtele C; Totzke F; Hilgeroth A
Bioorg Med Chem Lett; 2012 Nov; 22(22):6914-8. PubMed ID: 23039927
[TBL] [Abstract][Full Text] [Related]
2. Approaches to a multitargeting drug development: first profiled 3- ethoxycarbonyl-1-aza-9-oxafluorenes representing a perspective compound class targeting Alzheimer disease relevant kinases CDK1, CDK5 and GSK-3β.
Hilgeroth A; Tell V; Kramer S; Totzke F; Schachtele C
Med Chem; 2014; 10(1):90-7. PubMed ID: 23477782
[TBL] [Abstract][Full Text] [Related]
3. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
[TBL] [Abstract][Full Text] [Related]
4. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and kinase inhibitory activity of novel substituted indigoids.
Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties.
Brachwitz K; Voigt B; Meijer L; Lozach O; Schächtele C; Molnár J; Hilgeroth A
J Med Chem; 2003 Feb; 46(5):876-9. PubMed ID: 12593668
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Novel Substituted Furopyridines as Inhibitors of Protein Kinases Related to Tau Pathology in Alzheimer´s Disease.
Schade N; Koch P; Ansideri F; Krystof V; Holzer M; Hilgeroth A
Med Chem; 2021; 17(8):844-855. PubMed ID: 34061007
[TBL] [Abstract][Full Text] [Related]
8. Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay.
Holzer M; Schade N; Opitz A; Hilbrich I; Stieler J; Vogel T; Neukel V; Oberstadt M; Totzke F; Schächtele C; Sippl W; Hilgeroth A
Molecules; 2018 Sep; 23(9):. PubMed ID: 30213139
[TBL] [Abstract][Full Text] [Related]
9. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
Vandromme L; Piguel S; Lozach O; Meijer L; Legraverend M; Grierson DS
Bioorg Med Chem Lett; 2006 Jun; 16(12):3144-6. PubMed ID: 16616489
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
11. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
Zhang X; Hernandez I; Rei D; Mair W; Laha JK; Cornwell ME; Cuny GD; Tsai LH; Steen JA; Kosik KS
J Biol Chem; 2013 Jul; 288(30):22042-56. PubMed ID: 23737518
[TBL] [Abstract][Full Text] [Related]
12. Drug Development of Small-Molecule Inhibitors of AD-Relevant Kinases as Novel Perspective Multitargeted Approach.
Tell V; Hilbrich I; Holzer M; Totzke F; Schachtele C; Slynko I; Sippl W; Hilgeroth A
Curr Alzheimer Res; 2016; 13(12):1330-1336. PubMed ID: 27306698
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
Ye Q; Shen Y; Zhou Y; Lv D; Gao J; Li J; Hu Y
Eur J Med Chem; 2013 Oct; 68():361-71. PubMed ID: 23994329
[TBL] [Abstract][Full Text] [Related]
14. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
15. Targeting Tau Hyperphosphorylation
Turab Naqvi AA; Hasan GM; Hassan MI
Curr Top Med Chem; 2020; 20(12):1059-1073. PubMed ID: 31903881
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
[TBL] [Abstract][Full Text] [Related]
17. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β.
Ye Q; Li M; Zhou Y; Pang T; Xu L; Cao J; Han L; Li Y; Wang W; Gao J; Li J
Molecules; 2013 May; 18(5):5498-516. PubMed ID: 23669633
[TBL] [Abstract][Full Text] [Related]
19. Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.
Jin N; Yin X; Yu D; Cao M; Gong CX; Iqbal K; Ding F; Gu X; Liu F
Sci Rep; 2015 Feb; 5():8187. PubMed ID: 25641096
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
